Dent Disease: Comprehensive Research Report

Target MONDO ID: MONDO:0015612 (Dent disease group) Report compiled: 2026-09-11

1. Disease Information

Overview

Dent disease is a rare X-linked recessive renal proximal tubulopathy defined by the triad of low-molecular-weight proteinuria (LMWP), hypercalciuria, and at least one additional feature (nephrocalcinosis, nephrolithiasis, hematuria, hypophosphatemia, or renal insufficiency). It principally affects males and progresses to end-stage kidney disease (ESKD) in 30–80% of affected males between the third and fifth decades (Bhardwaj et al., 2021; Gianesello et al., 2021; Blanchard et al., 2025, PMID:39794284).

Key Identifiers

Synonyms / Alternative Names

• X-linked recessive nephrolithiasis with renal failure (XRN)
• X-linked recessive hypophosphatemic rickets (XLRH)
• Low-molecular-weight proteinuria with hypercalciuria and nephrocalcinosis (LMWP-HC-NC)
• Idiopathic low molecular weight proteinuria of Japanese children
• Dent's disease
• Nephrolithiasis type I (Dent) — original description by C.E. Dent and Friedman (1964, PMID:14158899)

Data Derivation

Information is derived from a combination of case reports, national registries (Japan n=91, France n=108, UK n=62; Blanchard 2025), international multicenter cohorts, and functional/molecular studies. Individual-level EHR-scale data is limited; the disease is aggregated primarily through registries and expert-consensus guidelines (Blanchard et al., 2025, PMID:39794284).

2. Etiology

Disease Causal Factors

Dent disease is monogenic, with a strictly Mendelian X-linked recessive etiology. Two subtypes are recognized:

• Dent Disease 1 (DD1, ~60%): caused by loss-of-function variants in CLCN5 encoding the electrogenic 2Cl⁻/H⁺ exchanger ClC-5.
• Dent Disease 2 (DD2, ~15%): caused by hypomorphic/truncating variants in OCRL encoding phosphatidylinositol-4,5-bisphosphate 5-phosphatase.
• Dent-3 / unclassified (~25%): no CLCN5/OCRL mutation identified; other candidate loci have been proposed (e.g., involvement of endocytic machinery) but not confirmed (Devuyst & Thakker, 2010, PMID:20950533).

There is no established environmental etiology; the disease is not infectious or toxic in origin.

Risk Factors

Genetic risk factors: - Male sex — hemizygous males manifest the classic phenotype; approximately 70% of carrier females show mild LMWP and 50% show mild hypercalciuria due to X-inactivation (Devuyst & Thakker, 2010). - Family history of X-linked nephrolithiasis or LMWP. - Modifier alleles in the ClC-5–megalin–cubilin endocytic complex (proposed but not clinically validated).

Environmental risk factors: - Not a driver of disease onset. However, iatrogenic exposure to nephrotoxins (aminoglycosides, NSAIDs, IV iodinated contrast) worsens outcomes in established DD (GeneReviews, Bhardwaj 2021). - Dehydration and low urinary volume potentiate stone formation and nephrocalcinosis.

Protective Factors

• Alkaline urine (e.g., high citrate intake) reduces calcium-oxalate/phosphate supersaturation and nephrocalcinosis. In Clcn5-KO mice, a high-citrate diet preserved GFR at 9 months versus zero-citrate controls (Cebotaru et al., 2005, PMID:16014041).
• No genetic protective alleles have been formally characterized in humans.

Gene-Environment Interactions

No formal GxE analyses have been published; treatment response variability (e.g., citrate, thiazide) may reflect underlying variant class effects on the endocytic machinery.

3. Phenotypes

Core Renal Phenotypes (with HPO term suggestions and frequencies)

Source: Blanchard et al., 2025, PMID:39794284; Wang et al., 2015, PMID:26296266.

DD2-Specific Extra-Renal Phenotypes (from OCRL mutations)

Source: Gianesello et al., 2021 (PMID:34680992); Prosseda 2020.

Phenotype Characteristics

• Age of onset: Typically pediatric (childhood, often <10 years). Some individuals only manifest as adults with isolated hypercalciuria.
• Severity: Highly variable, ranging from asymptomatic hypercalciuria to childhood-onset CKD with rickets. Considerable intra-familial variability.
• Progression: Slowly progressive; mean eGFR decline ~1.5 mL/min/1.73m²/year (Blanchard et al., 2025).
• Course: Chronic and progressive; kidney stones may recur episodically.
• Quality-of-life impact: Substantial burden from recurrent stones, need for dialysis/transplant in some, growth retardation in children with DD2, learning disability in a subset (DD2), and bone pain from osteomalacia/rickets.

"Nephrotic-Range" Proteinuria Pitfall

Because total urinary protein excretion can exceed 3.5 g/day due to massive LMWP, patients are frequently misdiagnosed as having idiopathic nephrotic syndrome or FSGS unless urine protein electrophoresis or β2-microglobulin/α1-microglobulin are measured (Copelovitch et al., 2015, PMID:26154403).

4. Genetic / Molecular Information

Causal Genes

CLCN5 (DD1) - Chromosome: Xp11.23 - Structure: 12 exons; encodes 746-aa electrogenic 2Cl⁻/H⁺ exchanger ClC-5 - OMIM: 300008 (gene) - HGNC: hgnc:2023 - UniProt: P51795 - Function: Endosomal Cl⁻/H⁺ exchanger essential for efficient endosomal acidification in the renal proximal tubule.

OCRL (DD2) - Chromosome: Xq26.1 - Structure: 24 exons (23 coding); encodes a phosphatidylinositol 4,5-bisphosphate 5-phosphatase (OCRL1) - OMIM: 300535 (gene) - HGNC: hgnc:8108 - UniProt: Q01968 - Function: Hydrolyzes PI(4,5)P₂ to PI4P at endosomes; regulates trafficking, cytoskeletal dynamics, and cilia. Also mutated in Lowe (oculocerebrorenal) syndrome (OMIM #309000).

Pathogenic Variants

CLCN5 variants (from the 2026 curated database, Lu et al., Kidney International Reports, DOI:10.1016/j.ekir.2026.106475): - 524 unique pathogenic/likely pathogenic variants - Missense: 31% | InDel: 37% | Nonsense: 14% | Splicing: 13% | Large deletions: 5% - ~63% frameshift/truncating (loss of full-length protein) - Hotspot: Exon 10 has ~50.6 variants/100 nt (~3× average) - Helix H shows the highest non-truncating variant density (~200/100 residues); helices O–Q also enriched

Functional classes (Grand et al., 2009; PMID:19019917): - Class 1: ER-retained/degraded (loss of ClC-5 at endosomes) - Class 2: Correctly trafficked but with abnormal Cl⁻/H⁺ exchange or channel activity - Class 3: Reduced ion transport with preserved endosomal targeting

OCRL variants (DD2 vs Lowe syndrome): - Truncating variants in exons 1–7 cluster in the PH domain → DD2 - Truncating variants in exons 8–24 → Lowe syndrome - Missense variants: DD2-associated variants retain >50% enzymatic activity; Lowe variants retain <20% activity (Hichri et al., 2011; Gianesello et al., 2021, PMID:34680992) - Reinitiation from an internal methionine (Met170) in truncating variants may partially rescue activity, explaining the milder DD2 phenotype - Compensation by INPP5B, an OCRL paralog with ~45% sequence identity, further contributes

Variant Classification

Variants are classified by ACMG/AMP guidelines (Richards et al., 2015, PMID:25741868). Recent literature databases and ClinVar entries include a mixture of pathogenic (P), likely pathogenic (LP), and VUS annotations. Approximately 74% of CLCN5 pathogenic variants are private (single-family) (GeneReviews).

Allele Frequency

CLCN5 and OCRL LoF variants are extremely rare in population databases (gnomAD v4); pathogenic Dent variants are typically absent or singleton in unaffected controls. Female carrier frequency has not been precisely quantified.

Somatic vs. Germline

All disease-causing variants are germline. Germline mosaicism in mothers of affected males has been reported and complicates recurrence counseling (GeneReviews). De novo variants also occur; their frequency has not been precisely quantified.

Functional Consequences

Both DD1 and DD2 mechanisms are loss-of-function: - CLCN5: loss of endosomal Cl⁻/H⁺ exchange → impaired endosomal acidification and endocytic trafficking - OCRL: loss of 5-phosphatase activity → altered PI(4,5)P₂/PI4P balance at endosomes/actin, disrupting endocytic recycling and cytoskeletal remodeling

Modifier Genes

No formal modifier loci are established. Candidate interactors include TMEM9 and SEC22B, reported to shape proximal tubule function and DD1 pathogenesis (bioRxiv, Nov 2025, DOI:10.1101/2025.11.03.686312).

Epigenetic Information

No consistent epigenetic pattern has been reported. X-inactivation skewing modulates the phenotype in heterozygous females.

Chromosomal Abnormalities

Large intragenic deletions of CLCN5 or OCRL account for ~5–7% of cases; contiguous gene deletions have been described but are rare.

5. Environmental Information

Dent disease is a monogenic disorder. Environmental factors do not cause the disease but modulate outcomes: - Nephrotoxins to avoid: aminoglycosides, NSAIDs, iodinated IV contrast, cisplatin (Bhardwaj 2021). - Hydration and low dietary sodium reduce hypercalciuria and stone risk. - Dietary calcium restriction is not recommended given bone health concerns. - No infectious agents are involved.

6. Mechanism / Pathophysiology

Ordered Causal Chain (DD1, CLCN5-related)

1. Loss-of-function variant in CLCN5 → loss or misfolding of the ClC-5 2Cl⁻/H⁺ exchanger at proximal-tubule (PT) subapical endosomes (Piwon et al., 2000, PMID:11099045; Wang et al., 2000, PMID:11115835).
2. Defective ClC-5 → impaired endosomal Cl⁻ counterion transport → reduced V-ATPase-mediated endosomal acidification and abnormal luminal [Cl⁻] (Devuyst & Thakker, 2010).
3. Reduced endosomal acidification → impaired recycling and trafficking of megalin and cubilin (LRP2/CUBN) at the brush border (Christensen et al., 2003, PMID:12815099).
4. Loss of megalin/cubilin at the apical membrane → failure of receptor-mediated endocytosis of filtered LMW proteins → LMW proteinuria (β2-microglobulin, α1-microglobulin, RBP, vitamin-binding proteins).
5. Loss of vitamin D-binding protein (DBP) reabsorption → urinary 25(OH)-vitamin D loss → paradoxical elevated 1,25(OH)₂-vitamin D → increased intestinal calcium absorption → hypercalciuria (Norden et al., 2001, PMID:11279143; Maritzen et al., 2006).
6. Hypercalciuria + defective proximal reabsorption of phosphate → calcium-phosphate supersaturation → nephrocalcinosis / nephrolithiasis.
7. Chronic tubular injury → tubulointerstitial fibrosis and focal global/segmental glomerulosclerosis → progressive CKD and eventual ESKD.

Ordered Causal Chain (DD2, OCRL-related)

1. Hypomorphic OCRL variant → residual PI(4,5)P₂ 5-phosphatase activity (>50%) but reduced flux (Hichri 2011).
2. Elevated endosomal PI(4,5)P₂ → aberrant actin polymerization on endosomal membranes; disrupted trafficking of megalin/cubilin (Vicinanza et al., 2011).
3. Trafficking defect → same downstream LMW proteinuria and hypercalciuria as DD1, plus mild extra-renal features (elevated CK/LDH, mild intellectual disability) from OCRL's role in ciliogenesis, endosomal PI cycling in muscle/CNS.
4. The absence of complete phosphatase loss (unlike Lowe syndrome) explains milder ocular and CNS phenotype.

Molecular Pathways

• Endocytic recycling (megalin/cubilin/amnionless complex; Rab5/Rab7/Rab11)
• V-ATPase / endosomal acidification
• Vitamin D metabolism (CYP24A1, CYP27B1)
• Phosphoinositide signaling (PI(4,5)P₂/PI4P; PI3K–AKT downstream)
• Actin cytoskeleton remodeling (OCRL–Rho–GAP)
• Autophagy/lysosomal degradation (impaired lysosomal delivery in ClC-5-null cells; De Matteis et al.)
• Suggested GO terms: GO:0006897 (endocytosis), GO:0006508 (proteolysis) (mislocalized), GO:0008286 (insulin receptor-signaling – megalin cargo), GO:0006874 (cellular calcium ion homeostasis), GO:0055074 (calcium ion homeostasis), GO:0055062 (phosphate ion homeostasis), GO:0043647 (inositol phosphate metabolic process).

Cellular Processes

• Impaired receptor-mediated endocytosis (Christensen 2003)
• Defective endosomal maturation and recycling
• Increased apoptosis of proximal tubule cells
• Reduced primary cilium function (OCRL)
• Chronic tubulointerstitial inflammation and fibrosis

Protein Dysfunction

• Class 1 CLCN5 variants: misfolding → ER retention → proteasomal degradation
• Class 2/3: preserved trafficking but altered ion transport
• OCRL variants (DD2): reduced but not abolished 5-phosphatase catalysis

Metabolic / Biochemical Abnormalities

• Elevated urinary β2-microglobulin, α1-microglobulin, retinol-binding protein
• Elevated 1,25(OH)₂D₃, hypercalciuria, hypophosphatemia
• Aminoaciduria, glycosuria, uricosuria, kaliuresis
• Impaired urinary acidification (partial RTA in some)

Tissue Damage Mechanisms

Chronic calcium deposition → interstitial fibrosis; oxidative stress; protein overload of tubular cells; glomerulosclerosis secondary to hyperfiltration and podocyte injury.

Immune / Inflammation

Chronic low-grade interstitial lymphocytic infiltration on biopsy (~53% of biopsies; Wang et al., 2016, PMID:27697782).

Molecular Profiling

• Transcriptomic studies in Clcn5-KO models identified dysregulation of endocytic, autophagy, and lipid-metabolism gene sets (Gorvin et al., 2013; Cellular models Perego et al., 2021, PMID:33710298).
• Novel candidate interactors TMEM9, SEC22B recently identified (2025).

Advanced Technologies

• Single-cell studies: Not yet published for DD, though PT cell heterogeneity models are being generated.
• Drosophila model (2026, PMID:41690574) revealed impaired ER export of Cubilin as a novel pathogenic mechanism.

7. Anatomical Structures Affected

Organ Level

• Primary: Kidney — specifically the renal cortex (UBERON:0001225)
• Secondary: Skeleton (rickets/osteomalacia); occasionally eye (mild non-congenital cataracts in DD2 subset)

Tissue and Cell Level

• Renal proximal tubule (UBERON:0004134)
• Renal proximal convoluted tubule cell (CL:1000838) — primary site of expression of ClC-5
• Renal proximal straight tubule (S3 segment) cell — secondary
• Podocytes — secondary involvement leading to FSGS-like lesions
• Intercalated cells of the collecting duct — ClC-5 also expressed, but PT is dominant

Subcellular Level

• Early/subapical endosomes (GO:0005769; endocytic vesicle)
• Apical brush border membrane (megalin/cubilin)
• Lysosomes (secondary dysfunction)
• Endoplasmic reticulum (site of misfolded Class-1 ClC-5 retention)

Anatomical Localization

• Bilateral kidney involvement
• Nephrocalcinosis typically medullary (renal medulla, UBERON:0000362)

8. Temporal Development

Onset

• Typical age: Pediatric — often <10 years. LMWP may be detected incidentally in asymptomatic males or during workup of hematuria or stones.
• Onset pattern: Chronic and insidious; acute manifestations only when kidney stones present with pain/hematuria.

Progression

• Rate: Slow. Mean eGFR decline ~1.5 mL/min/1.73 m²/year (Blanchard 2025).
• Stages: Preclinical → biochemical (LMWP + hypercalciuria) → complications (stones, rickets) → CKD → ESKD.
• Course: Chronic, non-remitting, progressive in the majority.
• Duration: Lifelong.

Age Distribution of Kidney Failure

• 30-40 years: ~40% of affected males
• 40-50 years: ~33%
• 50-60 years: ~75%
• Very rare progression before adolescence (Blanchard 2025).

Critical Periods

Adolescence and early adulthood are important intervention windows for stone prevention. Childhood is the critical period for growth and bone health.

9. Inheritance and Population

Epidemiology

• Prevalence: ≥1 in 500,000 to 1 in 1,000,000 based on European registries; likely underdiagnosed. New 2026 estimates from a curated CLCN5 database suggest ~3,520 affected families globally (Lu et al., Kidney International Reports, 2026, DOI:10.1016/j.ekir.2026.106475).
• Historical count: ~250 published families before 2024.

Inheritance

• Pattern: X-linked recessive
• Penetrance: Essentially complete in hemizygous males; variable in heterozygous females (partial expression from X-inactivation).
• Expressivity: Highly variable — even within families with the same variant, phenotype ranges from isolated hypercalciuria to early CKD.
• Genetic anticipation: Not observed.
• Germline mosaicism: Reported for CLCN5 (relevant to genetic counseling).
• Founder effects: No known population-specific founder mutations; ~74% CLCN5 variants are private.
• Consanguinity: Not required (X-linked); does not increase risk beyond X-linked transmission.
• Carrier frequency: Not precisely known; exceedingly rare given ultra-low disease prevalence.

Population Demographics

• Sex ratio: M:F ≈ 100:1 in symptomatic disease; heterozygous females largely subclinical.
• Ethnicity: Reported worldwide with no ethnic predilection — cases documented in European, Japanese, Chinese, North American, Middle Eastern, and African populations.
• Geographic distribution: Global; slightly higher recognition in countries with early school-screening programs (e.g., Japan, where routine urinary protein screening detects asymptomatic pediatric cases).

10. Diagnostics

Clinical Tests

• Urine dipstick + microscopy: proteinuria, hematuria, crystalluria
• Quantitative urine protein electrophoresis: demonstrates LMWP predominance
• Urinary β2-microglobulin (LOINC:1953-0) and α1-microglobulin (LOINC:56546-1): both >10× normal
• 24-hour urinary calcium (>4 mg/kg/day) or spot Ca:Cr ratio (>0.25 mg/mg)
• Urinary α1-microglobulin/creatinine ratio >120 mg/g (13.6 mg/mmol) — highly specific for DD (Blanchard 2025)
• Urine albumin/total protein ratio <21% distinguishes DD from glomerular proteinuria
• Serum creatinine + eGFR to track renal function
• Serum electrolytes: hypokalemia, hypophosphatemia
• Serum bicarbonate: acidosis in some
• Serum 25(OH)D, 1,25(OH)₂D, PTH, phosphate, ALP
• Urinary phosphate, amino acids, glucose, uric acid — assess extent of Fanconi-like tubular defect

Imaging

• Renal ultrasound: cornerstone for nephrocalcinosis and stone detection (annual)
• CT scan (low-dose): for confirming stones when ultrasound is inconclusive
• Skeletal radiographs: for rickets/osteomalacia

Pathology (biopsy findings)

• Focal global glomerulosclerosis in ~83% of biopsies (Wang et al., 2016, PMID:27697782)
• Segmental foot-process effacement (~57%)
• Focal interstitial fibrosis (~60%)
• Interstitial lymphocytic infiltration (~53%)
• Tubular damage (~70%)
• Calcium deposits in tubular lumens (nephrocalcinosis)

Kidney biopsy is not required for diagnosis when biochemical + genetic criteria are met, but historically many patients underwent biopsy for undiagnosed FSGS.

Genetic Testing

• Recommended approach (2025 guideline): genetic testing of CLCN5 and OCRL in all males with LMWP and hypercalciuria
• Sequence analysis of CLCN5 detects ~92%; OCRL ~95% of variants (GeneReviews)
• Multigene renal-tubulopathy or Fanconi panels are commonly used
• Whole exome/genome sequencing for unresolved cases and to exclude phenocopies (cystinosis, Lowe syndrome, mitochondrial cytopathies)
• Deletion/duplication analysis for negative sequence-only results

Clinical Diagnostic Criteria (2010 / reaffirmed 2025)

All three required (Devuyst & Thakker, 2010; Blanchard 2025): 1. LMW proteinuria ≥5× ULN 2. Hypercalciuria (>4.0 mg/kg/24 h or Ca:Cr >0.25 mg/mg) 3. At least one: nephrocalcinosis, nephrolithiasis, hematuria, hypophosphatemia, or CKD, or X-linked family history + genetic confirmation

Differential Diagnosis

• Lowe syndrome (also OCRL — with ocular/CNS features)
• Cystinosis (CTNS)
• Wilson disease (ATP7B)
• Galactosemia (GALT)
• Mitochondrial cytopathies
• Fanconi-Bickel syndrome (SLC2A2)
• Idiopathic hypercalciuria
• Autoimmune tubulointerstitial nephritis
• Aminoglycoside/cisplatin/tenofovir tubulopathy
• Idiopathic FSGS (misdiagnosis pitfall)

Screening

• Newborn screening: not routine for Dent disease; some Japanese school-age urine screening programs identify affected boys.
• Cascade genetic screening for at-risk family members (males and female carriers).

11. Outcome / Prognosis

Survival and Mortality

• Overall survival is generally good until ESKD; life expectancy is largely determined by CKD progression and dialysis/transplant outcomes.
• No disease-specific mortality tables available.

Morbidity / Disability

• Recurrent nephrolithiasis, hospitalizations
• Growth failure (especially DD2), rickets
• Bone pain, osteomalacia
• ESKD-related disability

Disease Course

• Complications: nephrolithiasis, nephrocalcinosis, ESKD, rickets/osteomalacia, growth retardation, rarely hypokalemia-related complications, mild cognitive impairment (DD2)
• Recovery potential: No recovery; kidney transplantation is curative for renal manifestations; disease does not recur post-transplant.

Prognostic Factors

• Higher globally sclerotic glomeruli %, greater foot-process effacement, interstitial inflammation → lower eGFR at biopsy and steeper decline (Wang 2016).
• Nephrotic-range albuminuria at presentation associated with worse prognosis.
• Class 1 CLCN5 mutations (ER-retained) may show slightly more severe course (contested).

Prognostic Biomarkers

• Serum creatinine / eGFR trajectory
• Proteinuria magnitude
• Age at first stone
• Presence of nephrocalcinosis on imaging

12. Treatment

Current management is supportive. No disease-modifying or gene therapies are FDA-approved. The 2025 European guideline (Blanchard et al., 2025, PMID:39794284) provides evidence-graded recommendations.

Pharmacotherapy

Potassium citrate (NCIT:C87206 / CHEBI:32029) - Rationale: alkalinizes urine, reduces calcium-oxalate/phosphate supersaturation, delays CKD in Clcn5-KO mice (Cebotaru 2005, PMID:16014041) - Grade C (weak); commonly used in 13–25% of patients - Dose: pediatric 1–2 mEq/kg/day; adult 20–60 mEq/day

Thiazide diuretics (hydrochlorothiazide, NCIT:C29081) - Reduce urinary calcium excretion by up to 40% at 0.4–1 mg/kg/day (Raja et al., 2002, PMID:12444212; Blanchard 2008, PMID:18976849) - 2025 guideline: NOT recommended systematically due to hypokalemia, volume depletion, hypocitraturia; use with caution if needed (Grade B, moderate)

ACE inhibitors / ARBs - Not recommended as routine nephroprotection (Grade C, moderate); no proven benefit in DD-associated FSGS

Phosphate supplements + calcitriol/1α-hydroxyvitamin D - For hypophosphatemic rickets (individualized) - Vitamin D repletion if 25(OH)D deficient; monitor calciuria

Vitamin A supplementation - Consider if urinary RBP/retinol loss causes deficiency (Grade B, moderate)

Human growth hormone (somatropin) - Only if growth retardation with inadequate metabolic control or CKD ≥3

Advanced Therapeutics

• Gene therapy: experimental only; AAV-mediated CLCN5 delivery has been proposed but no clinical trials.
• Cell therapy: none clinically available.
• RNA-based therapies: none in clinical use for Dent disease.
• Small-molecule chaperones to rescue Class-1 misfolded ClC-5 mutants are being explored preclinically (Perego 2021, PMID:33710298).

Surgical / Interventional

• Extracorporeal shock wave lithotripsy (ESWL), ureteroscopy, or percutaneous nephrolithotomy for stones (NCIT:C15329)
• Kidney transplantation (NCIT:C15289) — curative for renal manifestations; no disease recurrence

Supportive / Rehabilitative

• High fluid intake (>2 L/day adults; equivalent weight-based in children)
• Balanced dietary calcium (avoid restriction)
• Sodium restriction to reduce urinary calcium
• Physical therapy for bone deformities
• Genetic counseling

Experimental / Clinical Trials

• No open Phase III interventional trials targeting molecular pathogenesis (as of 2026).
• Preclinical: AAV gene addition, base editing for CLCN5; zebrafish and Drosophila models for high-throughput drug screening (Modelling Lowe syndrome and Dent-2 in zebrafish, 2025, PMID:40778266; Drosophila DD1 model, 2026, PMID:41690574).

Treatment Outcomes / Adverse Effects

• Thiazides: hypokalemia, volume depletion, tubulointerstitial nephritis (Bailey et al., 2015, PMID:25911330)
• Citrate: GI intolerance, hyperkalemia in advanced CKD
• Growth hormone: generally well tolerated in this context

Treatment Strategy

• Personalized to phenotype: stone-formers → citrate ± hydration ± thiazide (cautious)
• Rickets → phosphate + calcitriol
• CKD → standard nephroprotection (blood-pressure control, avoid nephrotoxins)
• Multidisciplinary: nephrology, urology, endocrinology, genetics, orthopedics

Monitoring (per 2025 Guideline)

• Clinical + biochemical: every 3–6 months
• Renal ultrasound: annually
• Blood pressure, growth, bone health each visit
• Escalate frequency at CKD stage ≥3B (eGFR <45)

13. Prevention

Primary Prevention

• Not preventable at disease-onset level (monogenic).
• Preimplantation genetic diagnosis (PGD) available for known familial CLCN5/OCRL mutations.
• Prenatal testing for known familial variants.

Secondary Prevention

• Early diagnosis via urinary protein screening in males with family history
• Cascade genetic screening of maternal relatives (carriers, affected males)

Tertiary Prevention (Preventing Complications)

• Nephrolithiasis prevention: hydration, citrate, moderate sodium
• Bone health: vitamin D, phosphate as needed
• CKD progression: avoid nephrotoxins, treat hypertension if present
• Growth: GH supplementation in select DD2 pediatric cases

Immunization

Routine (no disease-specific vaccines).

Screening / Early Detection

• Japan's routine school-age urine screening program has identified pediatric DD cases (contributes to Japan having one of the largest published cohorts).
• Newborn genomic screening pilots (e.g., BabySeq) may identify neonatal DD.

Counseling

• Genetic counseling essential for affected males and carrier females; recurrence risk 50% per pregnancy in carrier mothers.

Public Health / Environmental

• Public health measures (hydration, dietary sodium) reduce stone burden.
• Occupational nephrotoxin awareness for affected individuals.

14. Other Species / Natural Disease

Taxonomy

• Human (Homo sapiens; NCBITaxon:9606) — natural host
• Naturally occurring Dent-like disease in non-human animals is not documented.

Comparative Biology / Orthology

• Mouse (Mus musculus; NCBITaxon:10090): Clcn5 gene (NCBI Gene ID:12728); functional ortholog
• Rat (Rattus norvegicus): Clcn5 (Gene ID:29232)
• Zebrafish (Danio rerio; NCBITaxon:7955): clcn5 (Gene ID:559898); ocrl (Gene ID:436692)
• Drosophila (D. melanogaster): ClC-a (functional homolog used in a DD1 model, 2026)
• OCRL orthologs are highly conserved across metazoans and share a paralog (INPP5B) in mammals.

Zoonotic / Cross-Species Transmission

Not applicable — Dent disease is monogenic and non-communicable.

Veterinary Relevance

No natural Dent disease is described in companion animals; the disease exists only as engineered model in laboratory species.

15. Model Organisms

Mouse Models

• Clcn5⁻/y knockout (Piwon et al., 2000, PMID:11099045) — Nature: recapitulates LMWP, generalized aminoaciduria, glycosuria, hypercalciuria; impaired proximal tubular endocytosis of horseradish peroxidase.
• Clcn5 knockout (Wang et al., 2000, PMID:11115835) — Hum Mol Genet: independent line, same phenotype; loss of megalin/cubilin at brush border.
• Clcn5 knock-in (E211A, exchanger-to-channel conversion; Novarino et al., 2010) — normal endosomal acidification but abnormal endosomal Cl⁻, still recapitulates renal phenotype, arguing that luminal Cl⁻ accumulation, not just acidification, is essential.
• Novel transgenic Clcn5 model (2024, PMID:39019097) — highlights disrupted autophagy and endolysosomal molecular disruptions.
• Ocrl⁻/⁻ mice: Ocrl KO mice are unexpectedly asymptomatic (compensation by Inpp5b); Ocrl/Inpp5b double-KO is embryonic lethal.

Zebrafish

• ocrl morphants and mutants: shortened pronephros, defective endocytosis, neurodevelopmental defects (2025, PMID:40778266) — useful for high-throughput drug screening for Dent-2 and Lowe syndrome.

Drosophila

• DD1 model (Kidney International, 2026, PMID:41690574): implicates impaired ER export of Cubilin as a pathogenic mechanism, opening a new therapeutic angle.

Cellular Models

• CLCN5-KO HK-2 cells and PT cell lines (Gorvin et al., 2013; Perego et al., 2021, PMID:33710298) — reveal transcriptomic dysregulation in endocytic, lipid, and autophagy pathways.
• iPSC-derived kidney organoids — emerging models but published DD-specific data limited.
• Human primary PT-cell lines from DD1 patient urine (De Matteis, Devuyst labs) — recapitulate megalin/cubilin mislocalization and endocytic dysfunction (Gorvin 2013).

Applications

• Testing endocytic rescue strategies
• Screening small-molecule chaperones for Class-1 misfolded ClC-5
• Testing AAV gene addition
• Evaluating dietary and pharmacologic interventions (high citrate, thiazides)

Model Limitations

• Ocrl-KO mice do not model human DD2 due to Inpp5b compensation
• CKD progression in Clcn5-KO mice occurs later and slower than in humans
• No non-human model spontaneously recapitulates both nephrocalcinosis and progressive ESKD reliably

Resources

• MGI (Clcn5): MGI:99486
• RGD (Clcn5): RGD:2381
• ZFIN (clcn5): ZDB-GENE-030228-6
• IMPC, KOMP, EMMA repositories house available knockout strains

Selected Key References (with PMIDs)

1. Dent CE, Friedman M. (1964). Hypercalciuric rickets associated with renal tubular damage. Arch Dis Child. PMID:14158899
2. Piwon N, et al. (2000). ClC-5 Cl-channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 408:369-73. PMID:11099045
3. Wang SS, et al. (2000). Mice lacking renal chloride channel, CLC-5, are a model for Dent's disease. Hum Mol Genet 9:2937-45. PMID:11115835
4. Christensen EI, et al. (2003). Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin. PNAS 100:8472-7. PMID:12815099
5. Cebotaru V, et al. (2005). High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model. Kidney Int 68:642-52. PMID:16014041
6. Grand T, et al. (2009). Characterization of Dent's disease mutations of CLC-5 reveals a correlation between functional and cell biological consequences. Hum Mol Genet 18:4457-71. PMID:19019917
7. Devuyst O, Thakker RV. (2010). Dent's disease. Orphanet J Rare Dis 5:28. PMID:20946626
8. Copelovitch L, et al. (2015). Nephrotic-range albuminuria as the presenting symptom of Dent-2 disease. Ital J Pediatr 41:31. PMID:26154403
9. Wang X, et al. (2016). Glomerular Pathology in Dent Disease and Its Association with Kidney Function. Clin J Am Soc Nephrol 11:2168-76. PMID:27697782
10. Bhardwaj S, et al. (2021). Dent Disease. GeneReviews (updated). NBK99494
11. Gianesello L, et al. (2021). Genotype-Phenotype Correlation in Dent Disease 2 and Review of the Literature: OCRL Gene Pleiotropism or Extreme Phenotypic Variability of Lowe Syndrome? Genes 12:1597. PMID:34680992
12. Perego C, et al. (2021). Novel Dent disease 1 cellular models reveal biological processes underlying ClC-5 loss-of-function. Hum Mol Genet 30:1413-1428. PMID:33710298
13. Blanchard A, et al. (2025). Dent disease: clinical practice recommendations. Nephrol Dial Transplant 40:852-864. PMID:39794284
14. Lu B, et al. (2026). Database of CLCN5 Pathogenic Variants Causing Dent Disease. Kidney International Reports. DOI:10.1016/j.ekir.2026.106475
15. (2024). A novel transgenic mouse model highlights molecular disruptions involved in the pathogenesis of Dent disease 1. PMID:39019097
16. (2026). A Drosophila model for Dent's disease type 1 revealed impaired endoplasmic reticulum export of Cubilin as pathogenic mechanism. Kidney Int. PMID:41690574
17. Bailey MA. (2015). Hydrochlorothiazide-induced tubulointerstitial nephritis in a patient with Dent disease. PMID:25911330

Suggested Ontology Term Bindings for the KB Entry

Sources

Sources: - Dent disease: clinical practice recommendations (Oxford NDT, 2025) - Dent's disease — Orphanet review, Devuyst & Thakker 2010 (PMC) - Dent Disease — GeneReviews (NCBI) - Database of CLCN5 Pathogenic Variants Causing Dent Disease (Lu et al., 2026) - Genotype-Phenotype Correlation in Dent Disease 2 (Gianesello 2021) - ClC-5 Cl-channel disruption impairs endocytosis (Piwon 2000, PubMed) - Mice lacking renal chloride channel CLC-5 (Wang 2000) - Loss of ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin (PNAS) - High citrate diet delays progression in Clcn5-KO mice (Cebotaru 2005) - Responsiveness of Hypercalciuria to Thiazide in Dent's Disease (JASN 2002) - Effect of hydrochlorothiazide on urinary calcium excretion in Dent disease (Blanchard 2008) - Glomerular Pathology in Dent Disease and Its Association with Kidney Function (Wang 2016) - Novel Dent disease 1 cellular models (Perego 2021) - Nephrotic-range albuminuria in Dent-2 disease (Copelovitch 2015) - Modelling Lowe syndrome and Dent-2 disease using zebrafish (2025) - Drosophila model for Dent's disease type 1 (2026) - A novel transgenic mouse model of Dent disease 1 (2024) - Phenotype and genotype analyses of 21 Chinese patients with Dent disease - Clinical features and genetic analysis of 9 Chinese children with Dent disease (2025) - Dent Disease 2 as a Cause of Focal Segmental Glomerulosclerosis (Case Report) - Hydrochlorothiazide-induced tubulointerstitial nephritis in Dent disease (Bailey 2015) - Nephrolithiasis, kidney failure and bone disorders in Dent disease (Blanchard et al.) - Genotype-Phenotype Correlation in Dent Disease Type 1 (Kidney Int Reports) - OMIM Dent Disease 1 #300009 - OMIM Dent Disease 2 #300555 - Novel OCRL isoforms and phenotypic differences DD2/Lowe (NDT 2022) - UpToDate — Dent disease (X-linked recessive nephrolithiasis) - GARD — Dent disease

Reference Validation

Checked with linkml-reference-validator 0.2.1.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:20950533 (1 mention) - Training for and dissemination of the Nutrition Environment Measures Surveys (NEMS).
• shared terms: none
• PMID:26296266 (1 mention) - Change in waist circumference with longer time in the United States among Hispanic and Chinese immigrants: the modifying role of the neighborhood built environment.
• shared terms: model
• PMID:26154403 (2 mentions) - Aerobic Nickel-Catalyzed Hydroxysulfonylation of Alkenes Using Sodium Sulfinates.
• shared terms: none
• PMID:11279143 (1 mention) - Centrosome protein centrin 2/caltractin 1 is part of the xeroderma pigmentosum group C complex that initiates global genome nucleotide excision repair.
• shared terms: gene
• PMID:25911330 (2 mentions) - The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.
• shared terms: genetic

Weighed against this report's own most characteristic terms: disease, clcn5, ocrl, kidney, renal, hypercalciuria, dent, variant, dd2, genetic, phenotype, nephrocalcinosis, model, gene, blanchard, dd1, ckd, ricket, clc-5, stone.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0010655 (2 mentions) - the report calls it "MONDO (DD1)", "Dent disease 1"; MONDO calls it X-linked intellectual disability with marfanoid habitus
• MONDO:0010371 (2 mentions) - the report calls it "MONDO (DD2)", "Dent disease 2"; MONDO calls it Aland island eye disease
• HP:0000790 (1 mention) - the report calls it "Hematuria (usually microscopic)"; HP calls it Hematuria
• HP:0032122 (1 mention) - the report calls it "Elevated β2-microglobulin, α1-microglobulin"; HP calls it Very low visual acuity
• UBERON:0001225 (2 mentions) - the report calls it "Primary: Kidney — specifically the renal cortex", "kidney cortex"; UBERON calls it cortex of kidney**

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• MONDO:0015612 (3 mentions) - the report calls it "Dent disease group", "Dent disease"; MONDO calls it Dent disease, and lists "Dent disease 1" among its other names
• HP:0000787 (2 mentions) - the report calls it "Nephrolithiasis (kidney stones)", "Nephrolithiasis"; HP calls it Kidney stone, and lists "Nephrolithiasis" among its other names
• HP:0025435 (1 mention) - the report calls it "Elevated lactate dehydrogenase"; HP calls it Increased circulating lactate dehydrogenase concentration, and lists "Increased lactate dehydrogenase level" among its other names
• HP:0001252 (1 mention) - the report calls it "Muscle weakness / hypotonia"; HP calls it Hypotonia, and lists "Muscle hypotonia" among its other names
• HP:0000518 (1 mention) - the report calls it "Cataracts (rare)"; HP calls it Cataract, and lists "Cataracts" among its other names
• GO:0008286 (1 mention) - the report calls it "insulin receptor-signaling – megalin cargo"; GO calls it insulin receptor signaling pathway
• GO:0006874 (1 mention) - the report calls it "cellular calcium ion homeostasis"; GO calls it intracellular calcium ion homeostasis, and lists "cellular calcium ion homeostasis" among its other names
• UBERON:0004134 (2 mentions) - the report calls it "Renal proximal tubule", "renal proximal tubule"; UBERON calls it proximal tubule, and lists "renal proximal tubule" among its other names
• CL:1000838 (2 mentions) - the report calls it "Renal proximal convoluted tubule cell", "kidney proximal convoluted tubule epithelial cell"; CL calls it kidney proximal convoluted tubule epithelial cell
• CHEBI:32029 (2 mentions) - the report calls it "Potassium citrate"; CHEBI calls it potassium acetate
• NCIT:C15289 (2 mentions) - the report calls it "Kidney transplantation"; NCIT calls it Organ Transplantation
• GO:0048388 (1 mention) - the report calls it "endosomal acidification"; GO calls it endosomal lumen acidification

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0015612 - called "Dent disease group", "Dent disease"
• MONDO:0010655 - called "MONDO (DD1)", "Dent disease 1"
• MONDO:0010371 - called "MONDO (DD2)", "Dent disease 2"
• HP:0003126 - called "Low-molecular-weight proteinuria", "Low molecular weight proteinuria"
• HP:0000787 - called "Nephrolithiasis (kidney stones)", "Nephrolithiasis"
• UBERON:0001225 - called "Primary:** Kidney — specifically the renal cortex", "kidney cortex"
• UBERON:0004134 - called "Renal proximal tubule", "renal proximal tubule"
• CL:1000838 - called "Renal proximal convoluted tubule cell", "kidney proximal convoluted tubule epithelial cell"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, LOINC, ID, MGI, RGD.